Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZELA trial of zelpultide alfa for prevention of bronchopulmonary dysplasia in high-risk preterm neonates
2024-513420-41-00Phase 3Authorised
- Sponsor
- Airway Therapeutics
- Start
- Jan 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of zelpultide alfa in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by Airway Therapeutics. Primary endpoint: Incidence of grade 2 or grade 3 bronchopulmonary dysplasia or death at week 36 postmenstrual age. Planned start Jan 2025; status: authorised.
02
Drugs
zelpultide alfa
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2024-513420-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513420-41-00.